Pharmacotoxic psychosis after memantine in Parkinson's disease.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  The Lancet

• Publication date

  1991-10-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0140-6736(91)91888-2PMID 1681331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice

  2005cited by this paper
• (3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients

  2005cited by this paper
• Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.

  1991cited by this paper
• Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists.

  1987cited by this paper
• Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia.

  1980cited by this paper
• Distribution of metabolism of the potential anti-parkinson drug memantine in the human.

  1980cited by this paper
• Levodopa-induced psychosis: a kindling phenomenon.

  1978cited by this paper
• [Modern treatment of parkinsonism].

  1972cited by this paper

• Parkinson’s disease psychosis management: an evidence based, experience informed, pragmatic approach

  2024cites this paper
• Unveiling new secrets in Parkinson's disease: the glycatome.

  2023cites this paper
• Effect of the mGlu4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset

  2023cites this paper
• Metabotropic glutamate receptors in Parkinson's disease.

  2023cites this paper
• Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic.

  2022cites this paper
• Pharmacotherapy of Psychosis in Parkinson’s Disease

  2020cites this paper
• Psychopharmacology for Patients with Parkinson’s Disease and Deep Brain Stimulation: Lessons Learned in an Academic Center

  2019cites this paper
• A Stage-Based Approach to Therapy in Parkinson’s Disease

  2019cites this paper
• The Pharmacology of Visual Hallucinations in Synucleinopathies

  2019cites this paper
• Amantadine and antiglutamatergic drugs in the management of Parkinson's disease

  2016cites this paper
• Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management

  2016cites this paper
• Manage psychosis in Parkinson’s disease using a stepwise approach

  2016cites this paper
• Manage psychosis in Parkinson’s disease using a stepwise approach

  2016cites this paper
• Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test

  2015cites this paper
• Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy

  2015cites this paper
• Retrospective study on agitation provoked by memantine in dementia.

  2015cites this paper
• Therapies under investigation for treating Parkinson's disease psychosis

  2014cites this paper
• Glutamate in Parkinson's disease: Role of antiglutamatergic drugs

  2013cites this paper
• Development of NMDAR Antagonists with Reduced Neurotoxic Side Effects: a Study on GK11

  2013cites this paper
• WITHDRAWN: Auditory hallucination and agitation due to memantine in a patient with Alzheimer's disease: a case report.

  2012cites this paper
• Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist

  2011influential citation
• The future of psychopharmacology of depression.

  2010cites this paper
• A Validated Stability-indicating Reverse Phase HPLC Assay Method for the Determination of Memantine Hydrochloride Drug Substance with UV-Detection Using Precolumn Derivatization Technique

  2010cites this paper
• Psychopharmaka in Geriatrie und Gerontopsychiatrie

  2010cites this paper
• Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain.

  2008cites this paper
• The Role of Opioids on Motor Activity in Physio-pathological Conditions

  2008cites this paper
• Short Communication Memantine Agonist Action at Dopamine D2 High Receptors

  2008cites this paper
• [Efficacy of memantine in Parkinson's disease with dementia].

  2008cites this paper
• Memantine agonist action at dopamine D2High receptors

  2008cites this paper
• The after-effect of human theta burst stimulation is NMDA receptor dependent.

  2007cites this paper
• The Selective mGlu5 Receptor Antagonist MTEP, Similar to NMDA Receptor Antagonists, Induces Social Isolation in Rats

  2007cites this paper
• The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.

  2006cites this paper
• Visual hallucinations from the addition of riluzole to memantine and bupropion.

  2006cites this paper
• A Comparison of Effects of Fluoxetine and Nortriptyline on the Symptoms of Major Depressive Disorder

  2006cites this paper
• Suchttherapeutika zur Sucht

  2006cites this paper
• Development of subtle psychotic symptoms with memantine: a case report.

  2005cites this paper
• Do antihypertensives make tranylcypromine safer? Three case reports.

  2005cites this paper
• Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine

  2005cites this paper
• Use of olanzapine in anorexia nervosa.

  2005cites this paper
• Injection site pain with long-acting risperidone.

  2005cites this paper
• 0781 Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine

  2005cites this paper
• Amantadine and the glutamate hypothesis of schizophrenia Experiences in the treatment of neuroleptic malignant syndrome

  2005cites this paper
• Basal Ganglia and Its Relevance to Parkinson’s Disease

  2004cites this paper
• NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia.

  2004cites this paper
• Psychosis in nursing home patients with Parkinson's disease.

  2004cites this paper
• Glutamate and the glutamate receptor system: a target for drug action

  2003cites this paper
• Pharmacology of Glutamate Receptors

  2002cites this paper
• Neuroprotective Effect of Memantine in Different Retinal Injury Models in Rats

  2002cites this paper
• Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice

  1999cites this paper
• N-methyl-D-aspartate antagonists and drug discrimination.

  1999cites this paper
• Clinically available NMDA antagonist, memantine, attenuates tolerance to analgesic effects of morphine in a mouse tail flick test.

  1999cites this paper
• Preclinical Toxicity Study of Intrathecal Administration of the Pain Relievers Dextrorphan, Dextromethorphan, and Memantine in the Sheep Model

  1999cites this paper
• Sensitive and selective liquid chromatographic assay of memantine in plasma with fluorescence detection after pre-column derivatization.

  1999cites this paper
• Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.

  1999cites this paper
• The role of glutamate in dementia.

  1998cites this paper
• Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine.

  1998cites this paper
• Enhancement of in vivo binding of [123I]β‐CIT by MK‐801 in rat brain

  1998cites this paper
• Dopamine/glutamate interactions in Parkinson's disease.

  1997cites this paper
• The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence.

  1996cites this paper
• Dopaminerg-, muscarinerg-, glutamaterg-und serotonerg-induzierte Psychosen. Zur Behandlung pharmakotoxisch bedingter, psychischer Störungen bei der Antiparkinson-Therapie

  1996cites this paper
• Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists.

  1996cites this paper
• Clinical experience with excitatory amino acid antagonist drugs.

  1995cites this paper
• New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine

  1995cites this paper
• Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson' disease

  1995cites this paper
• Memantine prevents progressive functional neurodegeneration in rats.

  1995cites this paper
• Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?

  1994cites this paper
• Antagonists of Excitatory Amino Acid Receptors in the Treatment of Parkinson’s Disease

  1994cites this paper
• Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.

  1994cites this paper
• Glutamatergic drugs in Parkinson's disease.

  1994cites this paper
• The role of excitatory amino acids in experimental models of Parkinson's disease

  1994cites this paper
• Therapeutic potential of PCP receptor ligands

  1994cites this paper
• Clinical use of amantadine in brain injury rehabilitation.

  1994cites this paper
• Drugs affecting autonomic functions or the extrapyramidal system

  1993cites this paper
• Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines.

  1993cites this paper
• Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease

  1992cites this paper
• Dextromethorphan and parkinsonism.

  1992cites this paper
• NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.

  1992cites this paper